The Business Research Company’s report on the Daratumumab Or Darzalex Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How are market drivers shaping the future growth trajectory of the daratumumab or darzalex industry?
The rise in incidence of bone marrow cancer is expected to propel the growth of the daratumumab or darzalex market going forward. Bone marrow cancer refers to cancers that begin in the bone marrow, such as multiple myeloma and leukemia, where abnormal blood cell production disrupts normal body function. The rising incidence of bone marrow cancers can be attributed to an aging population, improved detection methods, and contributing factors such as environmental influences, lifestyle choices, and genetic predispositions. Daratumumab (Darzalex) helps in the treatment of multiple myeloma, a type of bone marrow cancer, by targeting and destroying abnormal plasma cells in the bone marrow. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization dedicated to eliminating cancer, there were projected to be 89,190 lymphoma cases compared to 89,010 in 2022. Moreover, 35,780 cases of myeloma compared to 34,470 in 2022. Therefore, the rise in incidence of bone marrow cancer is driving the growth of the daratumumab or darzalex market.
Rising Adoption Of Targeted Therapies And Biologics Driving Daratumumab Or Darzalex Market Growth
Rising adoption of biologics and targeted therapies is expected to propel the growth of the daratumumab or darzalex market going forward. Targeted therapies refer to a type of medical treatment that uses drugs or other substances to precisely identify and attack specific molecules involved in the growth and survival of cancer or other diseases. The adoption of biologics and targeted therapies is increasing due to the rising prevalence of chronic diseases and advancements in precision medicine, which enable more personalized, effective treatments. Daratumumab is utilized in targeted therapies due to its specific action on CD38, a protein highly expressed on the surface of malignant plasma cells in multiple myeloma. For instance, in December 2023, according to the Advanced Therapy Treatment Centers (ATTC), a UK-based network that works to bring new advanced therapy medicinal products (ATMPs) to patients, annual investments in advanced therapies rose by 31% in 2022, with the UK now accounting for 14% of all global commercial ATMP clinical trials. Therefore, rising adoption of biologics and targeted therapies is driving the growth of the daratumumab or darzalex market.
Access Your Free Sample of the Global Daratumumab Or Darzalex Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=19896&type=smp
What is the estimated market size of the daratumumab or darzalex sector by 2029, based on current forecasts?
The daratumumab or darzalex market size has grown rapidly in recent years. It will grow from $5,093.04 million in 2024 to $5,618.30 million in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to the adoption of multiple channels of research, increased feasibility of biomanufacturing operations, increased usage of monoclonal antibodies, increased number of strategic initiatives, and increased secretion of mAbs.
The daratumumab or darzalex market size is expected to see rapid growth in the next few years. It will grow to $8,189.36 million in 2029 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to increasing clinical evidence demonstrating, rising adoption in earlier treatment lines, increasing the demand for biologics, increasing patient awareness levels, growing incidence of blood cancer, and rising prevalence of chronic diseases. Major trends in the forecast period include technological advancements, new product launches, offerings of products and/or services, partnerships, mergers and acquisitions, advancements in radiation technologies, and collaborations.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=19896&type=smp
Who are the top players in the daratumumab or darzalex market?
Major companies operating in the daratumumab or darzalex market include Genmab A/S, Janssen Biotech Inc.
What are the major trends in the daratumumab or darzalex market?
The key trend in the daratumumab or darzalex market is focusing on a shift in oncology treatments towards early intervention solutions such as combination therapies to enhance efficacy in treating multiple myeloma and other cancers. Combination therapies refer to treatment strategies that use two or more therapeutic agents with different mechanisms of action, often synergistically, to enhance efficacy, minimize resistance, and improve patient outcomes while potentially reducing adverse effects compared to monotherapy. For instance, in July 2024, Johnson & Johnson, a US-based pharmaceutical industry company, received U.S. FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation therapy in patients with newly diagnosed multiple myeloma (NDMM) eligible for autologous stem cell transplant (ASCT). This new approval provides a quadruplet therapy option at initial diagnosis, potentially improving patient outcomes.
Which geography holds the highest daratumumab or darzalex market share?
North America was the largest region in the daratumumab or darzalex market in 2024. The regions covered in the daratumumab or darzalex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/daratumumab-or-darzalex-global-market-report
How do different segments contribute to the overall expansion of the daratumumab or darzalex market?
The daratumumab or darzalexmarket covered in this report is segmented –
1) By Drug Type: 100Mg Injection; 400Mg Injection
2) By Distribution Channel: Pharmacies; Hospital; Other Distribution Channels
3) By Application: Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma; Diffuse Large B Cell Lymphoma; Other Applications
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/customise?id=19896&type=smp
What defines the structure and scope of the daratumumab or darzalex market?
Daratumumab, or darzalex, refers to a monoclonal antibody used as a medication in the treatment of certain cancers, particularly multiple myelomas. It is designed to target and bind to CD38, a protein that is highly expressed on the surface of multiple myeloma cells, as well as other malignant and normal immune cells.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
